These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 22836278)

  • 1. Treatment failure in osteoporosis.
    Diez-Perez A; Adachi JD; Agnusdei D; Bilezikian JP; Compston JE; Cummings SR; Eastell R; Eriksen EF; Gonzalez-Macias J; Liberman UA; Wahl DA; Seeman E; Kanis JA; Cooper C;
    Osteoporos Int; 2012 Dec; 23(12):2769-74. PubMed ID: 22836278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One year in review 2018: progress in osteoporosis treatment.
    Figliomeni A; Signorini V; Mazzantini M
    Clin Exp Rheumatol; 2018; 36(6):948-958. PubMed ID: 30526765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Goal-directed treatment of osteoporosis in Europe.
    Kanis JA; McCloskey E; Branco J; Brandi ML; Dennison E; Devogelaer JP; Ferrari S; Kaufman JM; Papapoulos S; Reginster JY; Rizzoli R
    Osteoporos Int; 2014 Nov; 25(11):2533-43. PubMed ID: 25199574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of the guideline of the American College of Physicians on the treatment of osteoporosis.
    Kanis JA; Cooper C; Rizzoli R; Reginster JY
    Osteoporos Int; 2018 Jul; 29(7):1505-1510. PubMed ID: 29869039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of glucocorticoid-induced osteoporosis: What is new?
    Compston J
    Int J Rheum Dis; 2019 Sep; 22(9):1595-1597. PubMed ID: 31478605
    [No Abstract]   [Full Text] [Related]  

  • 6. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monitoring anti-osteoporotic therapy: bone mineral density or markers of bone turnover].
    Pedersen SB; Rand MS; Eiken PA; Jørgensen NR
    Ugeskr Laeger; 2018 Aug; 180(32):. PubMed ID: 30070630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs for the treatment of metabolic bone diseases.
    Drake MT; Cremers S; Russell RG; Bilezikian JP
    Br J Clin Pharmacol; 2019 Jun; 85(6):1049-1051. PubMed ID: 30950086
    [No Abstract]   [Full Text] [Related]  

  • 9. The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review.
    Peppone LJ; Hebl S; Purnell JQ; Reid ME; Rosier RN; Mustian KM; Palesh OG; Huston AJ; Ling MN; Morrow GR
    Osteoporos Int; 2010 Jul; 21(7):1133-49. PubMed ID: 19960185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Theoretical consideration of the effect of drug holidays on BMD and tissue age.
    Hernandez CJ; Lopez HK; Lane JM
    Osteoporos Int; 2014 May; 25(5):1577-84. PubMed ID: 24570296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of minodronic acid hydrate in patients with steroid-induced osteoporosis.
    Kitamura N; Shiraiwa H; Inomata H; Nozaki T; Ikumi N; Sugiyama K; Nagasawa Y; Karasawa H; Iwata M; Matsukawa Y; Takei M
    Int J Rheum Dis; 2018 Apr; 21(4):813-820. PubMed ID: 26929019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials.
    Chen L; Wang G; Zheng F; Zhao H; Li H
    Osteoporos Int; 2015 Sep; 26(9):2355-63. PubMed ID: 25944731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years.
    Bruyère O; Collette J; Rizzoli R; Decock C; Ortolani S; Cormier C; Detilleux J; Reginster JY
    Osteoporos Int; 2010 Jun; 21(6):1031-6. PubMed ID: 19813043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spanish consensus on treat to target for osteoporosis.
    Nogués X; Nolla JM; Casado E; Jódar E; Muñoz-Torres M; Quesada-Gómez JM; Canals L; Balcells M; Lizán L
    Osteoporos Int; 2018 Feb; 29(2):489-499. PubMed ID: 29177559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone-Targeted Therapy in Early Breast Cancer.
    Jerzak KJ; Raphael J; Desautels DN; Blanchette PS; Tyono I; Pritchard KI
    Oncology (Williston Park); 2018 Nov; 32(11):562-9. PubMed ID: 30474104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring pharmacological therapy for osteoporosis.
    Lewiecki EM
    Rev Endocr Metab Disord; 2010 Dec; 11(4):261-73. PubMed ID: 20143165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancel the denosumab holiday.
    McClung MR
    Osteoporos Int; 2016 May; 27(5):1677-82. PubMed ID: 26932443
    [No Abstract]   [Full Text] [Related]  

  • 18. Bone mineral density as a surrogate endpoint for fracture risk reduction in clinical trials of osteoporosis therapies: an update on SABRE.
    Black DM; Thompson AR; Eastell R; Bouxsein ML
    Lancet Diabetes Endocrinol; 2024 Jun; 12(6):371-373. PubMed ID: 38677307
    [No Abstract]   [Full Text] [Related]  

  • 19. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
    Abdelazim IA; Abdelrazak KM; Al-Kadi M; Yehia AH; Nusair BM; Faza MA
    Arch Osteoporos; 2014; 9():189. PubMed ID: 25037077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.